EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The cost effectiveness of mass drug therapy for intestinal helminths






PharmacoEconomics 8(1): 14-22

The cost effectiveness of mass drug therapy for intestinal helminths

This article reviews the principles involved in establishing the cost effectiveness of mass drug therapy for the major intestinal nematodes of man (Ascaris lumbricoides, Necator americanus, Ancylostoma duodenale, Trichuris trichiura) and the intestinal form of schistosomiasis (mainly Schistosoma mansoni and S. japonicum), as well as the extent to which the available studies have provided definitive answers. The article is presented under the headings: principles of cost-effectiveness analysis; the most efficient chemotherapy strategy; anthelmintic treatment versus other types of programme.

Accession: 002980986

PMID: 10155598

DOI: 10.2165/00019053-199508010-00004

Download PDF Full Text: The cost effectiveness of mass drug therapy for intestinal helminths



Related references

Turner, H.C.; Truscott, J.E.; Fleming, F.M.; Hollingsworth, T.Déirdre.; Brooker, S.J.; Anderson, R.M., 2016: Cost-effectiveness of scaling up mass drug administration for the control of soil-transmitted helminths: a comparison of cost function and constant costs analyses. The coverage of mass drug administration (MDA) for neglected tropical diseases, such as the soil-transmitted helminths (STHs), needs to rapidly expand to meet WHO's 2020 targets. We aimed to compare use of a cost function to take into account...

Dao, T.D., 1985: Cost-benefit and cost-effectiveness analysis of drug therapy. A model for cost-benefit analysis and cost-effectiveness analysis (CBA-CEA) of pharmaceutical intervention is presented, and CBA-CEA research methods reported in the literature are reviewed. The cost versus benefit and the cost effectiveness of dr...

Oqueka, T.; Supali, T.; Ismid, I.Suhariah.; Purnomo; Rückert, P.; Bradley, M.; Fischer, P., 2005: Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia. Background: Annual mass drug administration (MDA) using diethylcarbamizine (DEC, 6 mg/kg) combined with albendazole (alb, 400 mg) is recommended by the Global Programme to Eliminate Lymphatic Filariasis (GPELF). This strategy has been shown to be...

Speight, A.N., 1975: Cost-effectiveness and drug therapy. Tropical Doctor 5(2): 89-92

Lipman, A.G., 1984: The cost effectiveness of drug therapy. Hospital Formulary 19(10): 875-875

Yano, F.; Watanabe, S.; Hayashi, K.; Kita, T.; Yamamoto, M.; Kosuda, S.; Tanaka, Y., 2007: Cost-effectiveness analysis of antithyroid drug therapy, I-131 therapy and subtotal thyroidectomy for Graves' disease. The objective of this study was to assess the cost-effectiveness of antithyroid drug (ATD) therapy vs. radioiodine therapy (RIT) vs. subtotal thyroidectomy (STT) by calculating expected lifelong cost and utility based on Graves' disease pati...

Naismith, N.W., 1990: Measurement of cost-effectiveness of drug therapy. Medical Journal of Australia 153(9): 571-571

Katyal, V.K.; Parbhakar, M., 1993: Cost effectiveness of drug therapy in enteric fever. Journal of the Association of Physicians of India 41(5): 313-313

Phillips, D.J.; Hopkins, L.E., 1987: Determining total cost-effectiveness of drug therapy. American Journal of Hospital Pharmacy 44(1): 67-67

Spath, M.A.; O'Brien, B.J., 2002: Cost effectiveness of implantable cardioverter defibrillator therapy versus drug therapy for patients at high risk of sudden cardiac death. The implantable cardioverter defibrillator (ICD) is a therapy for patients at risk of sudden cardiac death due to ventricular tachycardia (VT) or ventricular fibrillation (VF). But the apparent high cost of ICD therapy relative to antiarrhythmic d...